JP2013522302A5 - - Google Patents

Download PDF

Info

Publication number
JP2013522302A5
JP2013522302A5 JP2013500127A JP2013500127A JP2013522302A5 JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5 JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013500127 A JP2013500127 A JP 2013500127A JP 2013522302 A5 JP2013522302 A5 JP 2013522302A5
Authority
JP
Japan
Prior art keywords
yeast
immunotherapy composition
interferon
based immunotherapy
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2013500127A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522302A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/028359 external-priority patent/WO2011115914A1/en
Publication of JP2013522302A publication Critical patent/JP2013522302A/ja
Publication of JP2013522302A5 publication Critical patent/JP2013522302A5/ja
Withdrawn legal-status Critical Current

Links

JP2013500127A 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療 Withdrawn JP2013522302A (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US31377410P 2010-03-14 2010-03-14
US31377610P 2010-03-14 2010-03-14
US31377510P 2010-03-14 2010-03-14
US61/313,775 2010-03-14
US61/313,776 2010-03-14
US61/313,774 2010-03-14
US37089910P 2010-08-05 2010-08-05
US61/370,899 2010-08-05
US40785910P 2010-10-28 2010-10-28
US61/407,859 2010-10-28
PCT/US2011/028359 WO2011115914A1 (en) 2010-03-14 2011-03-14 Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy

Publications (2)

Publication Number Publication Date
JP2013522302A JP2013522302A (ja) 2013-06-13
JP2013522302A5 true JP2013522302A5 (https=) 2014-05-01

Family

ID=44649537

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013500127A Withdrawn JP2013522302A (ja) 2010-03-14 2011-03-14 酵母系免疫療法を使用した感染症の薬理ゲノミクス及び治療反応性ガイド治療

Country Status (4)

Country Link
US (1) US20130121964A1 (https=)
EP (1) EP2547792A4 (https=)
JP (1) JP2013522302A (https=)
WO (1) WO2011115914A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008097863A2 (en) 2007-02-02 2008-08-14 Globeimmune, Inc. Methods for producing yeast-based vaccines
US8501167B2 (en) 2007-03-19 2013-08-06 Globeimmune, Inc. Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
US9006218B2 (en) 2010-02-12 2015-04-14 Chimerix Inc. Nucleoside phosphonate salts
CA2797601A1 (en) 2010-04-26 2011-11-10 Chimerix, Inc. Methods of treating retroviral infections and related dosage regimes
US20120196272A1 (en) * 2010-08-05 2012-08-02 Roche Molecular Systems, Inc. Prediction of HCV Viral Kinetics in Interferon-Free Treatment
US9254320B2 (en) 2010-12-17 2016-02-09 Globeimmune, Inc. Compositions and methods for the treatment or prevention of human adenovirus-36 infection
JP5745102B2 (ja) 2011-02-12 2015-07-08 グローブイミューン，インコーポレイテッド 慢性ｂ型肝炎感染症のための酵母系免疫療法組成物
MX350661B (es) 2011-03-17 2017-09-13 Us Health Composiciones inmunoterapeuticas de levadura-brachyuri.
CN103732250A (zh) 2011-06-14 2014-04-16 全球免疫股份有限公司 基于酵母的治疗或预防丁型肝炎病毒感染的组合物和方法
SG10201607663YA (en) 2011-08-17 2016-11-29 Globeimmune Inc Yeast-muc1 immunotherapeutic compositions and uses thereof
MX365418B (es) 2012-06-26 2019-06-03 Biodesix Inc Metodo por espectros de masa para la seleccion y descarte de pacientes de cancer para el tratamiento con terapias generadoras de respuestas inmunitarias.
EP2869823A4 (en) * 2012-07-03 2016-03-16 Chimerix Inc METHOD FOR THE TREATMENT OF RETROVIRUS INFECTIONS AND RELATED DOSING PLANS
CN102816838A (zh) * 2012-07-06 2012-12-12 吉林艾迪康医学检验所有限公司 用于检测丙型肝炎患者il28b snp12980275多态性的试剂盒
AU2014265873B2 (en) 2013-03-19 2019-01-17 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
US10226522B2 (en) 2013-08-30 2019-03-12 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
CA2948803A1 (en) * 2014-04-11 2015-10-15 Globeimmune, Inc. Yeast-based immunotherapy and type i interferon sensitivity
WO2016096800A1 (en) * 2014-12-18 2016-06-23 F. Hoffmann-La Roche Ag Biomarkers for hbv treatment response
CN107406857B (zh) 2015-01-09 2021-06-29 埃图比克斯公司 用于联合免疫治疗的方法和组合物
AU2016205208A1 (en) 2015-01-09 2017-07-06 Etubics Corporation Methods and compositions for ebola virus vaccination
JP6738319B2 (ja) * 2015-03-30 2020-08-12 雅史 溝上 インターフェロン治療効果予測方法及びそれを用いたｂ型肝炎患者の治療用医薬組成物
US11149087B2 (en) 2015-04-20 2021-10-19 Etubics Corporation Methods and compositions for combination immunotherapy
WO2017009303A1 (en) * 2015-07-15 2017-01-19 F. Hoffmann-La Roche Ag Biomarkers for hbv treatment response
AU2016303525B2 (en) 2015-08-03 2021-01-21 Globeimmune, Inc. Modified yeast-Brachyury immunotherapeutic compositions
RU2623151C2 (ru) * 2015-11-03 2017-06-22 Федеральное государственное казенное учреждение Главный клинический военный госпиталь ФСБ России Способ прогнозирования динамики фиброза печени у пациентов с хроническим гепатитом С, генотипом 1, не ответивших на лечение пегилированными интерферонами и рибавирином
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN119818663A (zh) 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
JP7417339B1 (ja) 2023-08-07 2024-01-18 シンバイオ製薬株式会社 アデノウイルス感染又はアデノウイルス感染に伴う疾患の治療

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7439042B2 (en) * 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
EP2460533A3 (en) * 2004-10-18 2014-01-08 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
SG163572A1 (en) * 2005-07-11 2010-08-30 Globeimmune Inc Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
JP5469744B2 (ja) * 2009-05-21 2014-04-16 メルク・シャープ・アンド・ドーム・コーポレーション インターフェロンアルファ応答に関連する遺伝子マーカー
US20100316608A1 (en) * 2009-06-15 2010-12-16 Vijayaprakash Suppiah Method of Determining A Response To Treatment With Immunomodulatory Composition

Similar Documents

Publication Publication Date Title
JP2013522302A5 (https=)
Sherman et al. Entecavir therapy for lamivudine‐refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks
JP2020100636A (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
JP2012513479A5 (https=)
Brunetto et al. Interferon therapy of chronic hepatitis B
JP2016531144A5 (https=)
JP2018531272A6 (ja) Ｈｂｖキャプシドアセンブリ阻害剤とインターフェロンの併用療法
JP2012519181A5 (https=)
Mallet et al. The impact of human immunodeficiency virus on viral hepatitis
JP2015517528A5 (https=)
JP2012503011A5 (ja) 慢性ｃ型肝炎ウイルス感染症のための酵母系免疫治療組成物
RU2015114543A (ru) Способы лечения гепатита с
JP2015528449A5 (https=)
JP2013529627A5 (https=)
RU2013148779A (ru) Лечение инфекции вируса гепатита в по отдельности или в комбинации с вирусом гепатита дельта и родственных заболеваний печени
RU2012136824A (ru) Способы лечения вирусной инфекции гепатита с
JP2019505553A5 (https=)
RU2015114566A (ru) Способы лечения гепатита с
CN102083435A (zh) 特拉匹韦给药方案
Marcellin et al. CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS: 476
Takkenberg et al. New developments in antiviral therapy for chronic hepatitis B
Chen et al. The current status of combination therapy of chronic hepatitis B.
Sokal et al. Chapter 6.1. Pediatric chronic hepatitis B and C: 30 years of ESPGHAN clinical research and recommendations
Mahtab et al. REP 9AC': A second generation HBsAg release inhibitor with improved tolerability: 424
Papatheodoridis et al. CHANGES OF SERUM HBSAG LEVELS IN HBEAG-NEGATIVE CHRONIC HEPATITIS B PATIENTS UNDER LONGTERM THERAPY WITH NUCLEOS (T) IDE ANALOGUE (S): 1458